Related Experiment Video

Updated: Jul 18, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Can we ensure the safe use of known human teratogens?: The iPLEDGE test case

Margaret A Honein1, Jill A Lindstrom, Sandra L Kweder

  • 1National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.

Drug Safety
|December 30, 2006
PubMed

Insights

Preventing birth defects from isotretinoin (Accutane) has been difficult. The iPLEDGE program, a comprehensive system, aims to reduce fetal exposure by controlling drug distribution and verifying pregnancy tests.

Area of Science:

  • Dermatology
  • Public Health
  • Pharmacovigilance

Background:

  • Isotretinoin is a crucial treatment for severe acne but poses significant teratogenic risks.
  • Previous risk management programs for isotretinoin failed to adequately prevent fetal exposures.
  • A 24-year history in the US highlights persistent challenges in managing isotretinoin's teratogenicity.

Purpose of the Study:

  • To evaluate the implementation and potential impact of the iPLEDGE risk management program.
  • To assess the effectiveness of a comprehensive distribution system in minimizing isotretinoin-induced teratogenicity.
  • To understand the challenges and benefits of a closed-loop system for a widely prescribed medication.

Main Methods:

  • Implementation of the iPLEDGE program, a mandatory registration and closed distribution system for isotretinoin.
  • Real-time verification of pregnancy test results prior to dispensing isotretinoin.
  • Mandatory registration of all stakeholders: patients, healthcare providers, pharmacies, and wholesalers.

Main Results:

  • The iPLEDGE program represents a comprehensive approach to controlling isotretinoin distribution.
  • Challenges in implementation were extensive due to the medication's widespread use.
  • The program aims to substantially reduce fetal exposure to isotretinoin.

Conclusions:

  • The iPLEDGE program is a significant advancement in managing isotretinoin's teratogenic risks.
  • A closed distribution system, despite implementation hurdles, holds substantial public health benefits.
  • Continued vigilance and adherence are crucial for the program's success in preventing birth defects.

More Related Videos

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing09:02

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing

Published on: June 9, 2017

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...